Lai C C, Miller J A, Miller E C, Liem A
Carcinogenesis. 1985 Jul;6(7):1037-45. doi: 10.1093/carcin/6.7.1037.
The hepatic DNA of 12-day-old male B6C3F1 (C57BL/6J X C3H/HeJ) mice given an i.p. dose of 0.06 or 0.11 mumol/g body weight of N-hydroxy-[3H]-2-acetylaminofluorene (N-hydroxy-AAF) contained at 9 h approximately 3 or 6 pmol of N-(deoxyguanosin-8-yl)-2-aminofluorene adducts per mg. Together the level of the two acetylated adducts N-(deoxyguanosin-8-yl)-2-acetylaminofluorene and 3-(deoxyguanosin-N2-yl)-2-acetylaminofluorene was less than or equal to 10% of this amount. The same doses of unlabeled carcinogen induced by 10 months a 100% incidence of hepatomas with averages of 10 and 15 hepatomas per mouse, respectively. Injection of 0.04 mumol/g body weight of pentachlorophenol (PCP) 45 min before the dose of N-hydroxy-AAF decreased the number of adducts in the DNA by 90% and the average number of hepatomas per liver by 80-90%. As compared to their normal male littermates, male brachymorphic B6C3F2 mice, which are deficient in hepatic 3'-phosphoadenosine-5'-phosphosulfate (PAPS), treated with N-hydroxy-AAF formed only 25% as many hepatic DNA adducts and developed only 10% as many hepatomas. Hepatic cytosols from 12-day-old B6C3F1 mice contained PAPS-dependent sulfotransferase activity for N-hydroxy-2-aminofluorene (N-hydroxy-AF), a previously unrecognized activity, as well as sulfotransferase activity for N-hydroxy-AAF; both activities were inhibited 60% by 1 microM and greater than or equal to 80% by 10 microM PCP. Cytosolic acetyl coenzyme A-dependent acetyltransferase activity for N-hydroxy-AF, cytosolic N,O-acyltransferase activity for N-hydroxy-AAF, and microsomal deacetylase for N-hydroxy-AAF were not significantly inhibited by PCP under these conditions. The above data strongly indicate that N-sulfoöxy-2-aminofluorene is the major ultimate electrophilic and carcinogenic metabolite of N-hydroxy-AAF in the livers of infant male B6C3F1 mice.
给12日龄雄性B6C3F1(C57BL/6J×C3H/HeJ)小鼠腹腔注射剂量为0.06或0.11μmol/g体重的N-羟基-[3H]-2-乙酰氨基芴(N-羟基-AAF),9小时后其肝脏DNA中每毫克约含3或6pmol的N-(脱氧鸟苷-8-基)-2-氨基芴加合物。N-(脱氧鸟苷-8-基)-2-乙酰氨基芴和3-(脱氧鸟苷-N2-基)-2-乙酰氨基芴这两种乙酰化加合物的水平合计不超过该量的10%。相同剂量的未标记致癌物在10个月时诱发肝癌的发生率为100%,每只小鼠平均分别有10个和15个肝癌。在给予N-羟基-AAF剂量前45分钟注射0.04μmol/g体重的五氯苯酚(PCP),可使DNA中加合物数量减少90%,每只肝脏中肝癌的平均数量减少80 - 90%。与正常雄性同窝小鼠相比,缺乏肝脏3'-磷酸腺苷-5'-磷酸硫酸酯(PAPS)的雄性短尾B6C3F2小鼠经N-羟基-AAF处理后,肝脏DNA加合物形成量仅为正常小鼠的25%,肝癌发生数量仅为正常小鼠的10%。12日龄B6C3F1小鼠的肝脏胞质溶胶含有对N-羟基-2-氨基芴(N-羟基-AF)的PAPS依赖性磺基转移酶活性(一种此前未被认识的活性)以及对N-羟基-AAF的磺基转移酶活性;1μM PCP可使这两种活性均被抑制60%,10μM PCP可使抑制率大于或等于80%。在这些条件下,PCP对N-羟基-AF的胞质溶胶乙酰辅酶A依赖性乙酰转移酶活性、对N-羟基-AAF的胞质溶胶N,O-酰基转移酶活性以及对N-羟基-AAF的微粒体脱乙酰酶活性均无显著抑制作用。上述数据有力地表明,N-磺氧基-2-氨基芴是幼年雄性B6C3F1小鼠肝脏中N-羟基-AAF的主要最终亲电致癌代谢物。